A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2023-07-10
AEs
3
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-09-11 (study day 45); relationship: not assessed
mild
assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-12-31 (study day 156); relationship: not assessed
severe
serious
assessed
Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-15 (study day 171); relationship: not assessed; serious criteria: life-threatening
Data queries
No data queries.